RE:RE:RE:Galectin's GR-MD-02 flunks mid-stage NASH study; shares off I mostly disagree! The two companies are very different. While a failure in PBI 4050 will of course hurt the sp of PLI - but not to the same extent as it did for GALT's failure with NASH. the reason is multifold.
1) PLI has MANY irons in the fire. The failure in only one indication for PBI 4050 is not the whole ballgame for PBI 4050 as it is being advanced for many different indications..
2) Very little of the current value of PLI comes from PBI 4050 - rather it is almost all (at this time) for the protein division - plasmiogen etc.that are largely already derisked.
3) The effect of a 4050 failure would also be greatly diminished if at that time the revenue flow from Pg and other proteins has already begun to flow.significantly
4) PLI is NOT a one trick pony.
Of course I very much hope that PLI will have much better luck with 4050, as early results seem to indicate, and not suffer such a failure at all.
So while their would surely be a drop on such bad news, PLI is much better insulated from a bad result in 4050 and would suffer a shallower and more temporary drop than Galt will suffer.
Glta
Stockman6767